Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Polynovo ( (AU:PNV) ).
PolyNovo Limited has announced a change in the director’s interest, with Dr. Robyn Elliott acquiring 20,000 ordinary fully paid shares through an on-market trade. This acquisition increases Dr. Elliott’s total holdings to 94,789 shares, reflecting a vote of confidence in the company’s prospects and potentially impacting investor perception positively.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, specializing in the development and commercialization of innovative biodegradable polymers for use in medical devices. The company’s primary product is the NovoSorb technology, which is used in various applications, including wound care and tissue regeneration.
Average Trading Volume: 2,731,955
Technical Sentiment Signal: Buy
Current Market Cap: A$1.05B
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.